Dr Reddy’s Laboratories has paused commercial supplies of its Semaglutide injection pens until November 2026 following an API impurity detection. This disruption has forced the company to cut its FY27 sales target to 6-7 million pens from the earlier 10-11 million. The gap in supply is expected to create near-term market share opportunities for competitors like Zydus Lifesciences and Sun Pharma in the domestic GLP-1 segment.
Dr Reddy’s Laboratories has informed stakeholders that it is halting commercial distribution of its Semaglutide product. This decision follows the identification of an impurity in the active pharmaceutical ingredient (API) that resulted in product batches failing to meet quality specifications. The company now expects to resume normal supply operations by early November 2026.
Impact on Sales Targets
This supply pause represents a material change in the company's near-term outlook for the weight-loss and diabetes drug segment. Dr Reddy’s has significantly revised its sales volume expectations for the fiscal year 2027, lowering the projected output of injection pens to between 6 million and 7 million units. This is a substantial reduction from the previous forecast of 10 million to 11 million units, reflecting the lost window of availability during the upcoming months.
Competitive Landscape in the GLP-1 Market
The Indian market for GLP-1 drugs is currently valued at approximately Rs 2,000 crore. While the segment is dominated by Eli Lilly’s Tirzepatide, which holds a 65% market share, the remaining segment is highly competitive with 31 brands vying for space. Among generic players, Torrent Pharma, Zydus Lifesciences, Dr Reddy's, and Sun Pharma have been key participants. Given the temporary supply exit of Dr Reddy's, industry observers anticipate that Zydus Lifesciences and Sun Pharma may experience a pickup in market share as they address the demand currently unmet by the supply delay.
International Developments and Growth Strategy
Beyond domestic operations, the global landscape for generic Semaglutide is evolving. Orbicular Pharmaceutical, working alongside Apotex, recently secured Health Canada approval for its generic version of the drug, which may allow it to gain a foothold in that market. Meanwhile, for Dr Reddy's, the financial impact of this disruption is being viewed by analysts through the lens of its broader pipeline. While the Semaglutide ramp-up was considered a near-term growth catalyst, the company’s mid-term outlook is increasingly linked to its biosimilars segment, specifically the potential launch of Abatacept in FY28.
Investors may monitor the progress of the corrective measures taken at the API facility to ensure a smooth resumption of supplies by November. Additionally, the ability of competitors to capture and retain the vacated market share during this period will be an important factor in understanding the long-term impact on the competitive dynamics of the GLP-1 sector in India.